ACADIA Pharmaceuticals
Trial Pipeline
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
NCT04292223
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03575052
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
NCT03482882
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
NCT02970292
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT01174004
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT00477672
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for ACADIA Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, ACADIA Pharmaceuticals is linked to 10 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 30% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 60% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for ACADIA Pharmaceuticals reports 6 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for ACADIA Pharmaceuticals is Parkinson's Disease Psychosis with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.